InvestSMART

Firebrick Pharma Limited (ASX:FRE)

ALERT: Price-sensitive ASX Announcement for FRE
Current share price for FRE : $0.039 -0.026 (-40%)+
Announcement
Release
28 Jan 2026 8:18AM
Price at Release
$0.065
Full Release
download
Summary
Firebrick Pharma Limited reported significant business activities in its December 2025 Quarterly Activity Report. During this period, the company began commercial manufacturing of the Nasodine Throat Spray, which gained export approval from the Therapeutic Goods Administration (TGA) and was launched in Singapore. Firebrick also reported several strategic initiatives, including expanded promotional efforts in the U.S., increased pharmacy distribution in Singapore, and the launch of Nasodine Throat Spray in Fiji. Financially, the company improved its cost efficiency, achieving a 15% reduction in base operating costs from the previous quarter and a 34% reduction year-over-year, while cash sales increased by 15% compared to the previous year. A shareholder sentiment survey revealed strong support for the company’s strategies, despite concerns over share price, and a user survey indicated high satisfaction with the Nasodine Nasal Spray. The company continues to explore new market opportunities, including potential approval in the Philippines and other Southeast Asian countries.
Key Points
  • Nasodine Throat Spray manufacturing and export approval.
  • Expansion in the U.S. and Singapore markets.
  • Launch in Fiji and exploration of Southeast Asian markets.
  • 15% reduction in base operating costs.
  • 15% increase in cash sales from previous year.
  • High user satisfaction with Nasodine Nasal Spray.
  • Strong shareholder support despite share price concerns.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.